DirectContract

Provider intelligence

Eli Lilly (Zepbound / tirzepatide)

Public employer-provider contracting intelligence involving Eli Lilly (Zepbound / tirzepatide). This page aggregates tracked arrangements, market context, reported economics, and primary sources from the DirectContract database.

1

Tracked contracts

—

Covered lives represented

1

Active or expanded

—

Highest reported savings

Tracked arrangements

Eli Lilly (Zepbound / tirzepatide) ↔ Self-insured employers (platform)

United States · 2026-03

Eli Lilly launched a direct-to-employer platform for tirzepatide (Zepbound) in March 2026, enabling self-insured employers to access GLP-1 obesity treatment at transparent prices without PBM intermediaries. The model cuts spread pricing and allows employers to offer the drug as a defined benefit at a predictable cost.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Reduced GLP-1 costs by bypassing PBM spread pricing

Primary source ↗
Explore all contractsGet the Friday briefing